Photodynamic Therapy for Eye Diseases: A Non-Invasive Approach to Vision Health

The global burden of eye diseases, especially is increasing sharply amid growing geriatric population. According to a report published in the National Library of Medicine (NLM), total number of people with age-related macular degeneration will likely reach around 288 million by 2040. This rising incidence of eye disorders is driving demand for advanced treatments, and one such breakthrough treatment is photodynamic therapy.

So what is photodynamic therapy in ophthalmology? It is a minimally invasive treatment that uses light and photosensitizing drugs to target and destroy abnormal blood vessels in the eye. PDT has become an effective tool for managing various vision-related conditions.

How Photodynamic Therapy Helps Vision?

Photodynamic therapy has the tendency to slow or prevent the progression of eye diseases. It works by selectively targeting abnormal blood vessels, such as those found in AMD. By doing so, it helps to stabilize and improve vision as well as prevent further vision loss.

Application of PDT in Ophthalmology

In the modern era, there is a growing trend of using photodynamic therapy for macular degeneration and other eye-related diseases. This is mainly due to its advantages like its non-invasive nature and fewer side effects.

• PDT for Age-Related Macular Degeneration (AMD)

A key application of PDT in ophthalmology is the treatment of age-related macular degeneration. Wet AMD occurs due to rapid growth of abnormal neovascular blood vessels under the macula. These blood vessels often leak blood and fluid that harm the central retina, causing vision loss.

PDT with verteporfin is used to tackle wet AMD. It helps target and destroy these abnormal blood vessels, thereby slowing disease progression and preserving vision.

• Photodynamic Therapy for Central Serous Chorioretinopathy

PDT is used to treat central serous chorioretinopathy (CSC), which is characterized by fluid accumulation beneath the retina. It effectively reduces fluid leakage, thereby improving vision.

Focal laser photocoagulation has been the mainstay treatment for chronic and recalcitrant CSC. However, lasers can cause some serious effects like RPE atrophy and symptomatic scotomas. To overcome these side effects, ophthalmologists opt for verteporfin PDT as it has the tendency to directly target the abnormality of choroidal hyperpermeability without damaging healthy tissues.

• PDT for Polypoidal Choroidal Vasculopathy (PCV)

PCV, just like AMD, causes polyp-like abnormal blood vessels. As a result, it can be treated by using PDT. This non-invasive treatment helps shrink polyps, thereby reducing the risk of bleeding and vision deterioration.

Doctors often use modalities like anti-VEGF, PDT, and laser photocoagulation to treat PCV. According to EVEREST Trial results, active subfoveal and juxtafoveal PCV should be treated with full fluence PDT along with three loading doses of anti-VEGF injection.

• PDT for Retinal Angiomatous Proliferation (RAP)

Photodynamic therapy is also used to treat retinal angiomatous proliferation. It has the tendency to destroy abnormal blood vessels associated with RAP.

• PDT for Ocular Histoplasmosis

Histoplasmosis, a fungal infection, can affect many organs of the body, including eyes. It can cause choroidal neovascularization (CNV), which sometimes leads to vision loss. PDT has proved to be a safe and effective option for treating this condition.

Benefits of PDT in Ophthalmology

Photodynamic therapy is becoming an ideal treatment for tackling eye diseases. This is mainly due to its benefits like

• Minimally invasive nature
• Selective targeting
• Quick procedure
• Faster healing times
• Repeatability
• Fewer side effects
• Cost-effectiveness

Laser vs Photodynamic Therapy for Eyes

 Photodynamic therapy has become a promising approach for treating various eye-related diseases. It effectively slows disease progression by selectively targeting abnormal blood vessels. Introduction of newer drug delivery systems and novel photosensitizers will help PDT to evolve further, offering new hope for patients with retinal disorders. It is also being used in combination with other therapies for better results.

Growing demand for non-invasive treatments for AMD and rise in photodynamic therapy success rates in ophthalmology will likely boost the PDT industry. As per Coherent Market Insight (CMI), the global photodynamic therapy industry is set to record a CAGR of 8.6% during the assessment period.